前立腺癌のEOD(Extent of disease)を含めた臨床病期と予後に関する検討

Abstract

前立腺癌288例において臨床病期分類, EOD分類と予後について検討した. 1)病期D2においてEOD1はEOD2, 3, 4に比べ有意に予後良好であり, EOD4はEOD1, 2, 3に比べ有意に予後不良であった. 2)病期D2, EOD1の予後はstage C, D1の予後とほぼ同等であった. 3)病期D2症例の治療開始3年後よりの予後には組織学的分化度の重要性が増すことが推測された

We analyzed the prognostic significance of clinical stage using extent of disease (EOD) grading system in 288 patients with prostate cancer between 1970 and 1994. The cause-specific survival rate for EOD4 was significantly lower (p < 0.01) than that for the other EOD categories. On the other hand, the cause-specific survival rate for EOD1 was significantly higher (p < 0.01) than that of the other EOD categories, and moreover, it was similar to the cause-specific survival rates for stage C and D1. The cause-specific survival rate of EOD1 and poorly differentiated cases was higher than that of EOD2 or 3 and well or moderately differentiated cases until 2 years after treatment, but after 3 years, the cause-specific survival rate for EOD1 and poorly differentiated cases was lower than that for EOD2 or 3 and well or moderately differentiated cases. These findings suggest that the volume of cancer is associated with the prognosis of prostate cancer that failed in radical treatment and that in stage D2, histological grade is more closely associated with the prognosis after treatment for 3 years.